Welcome to our dedicated page for THERMO FISHER SCIENTIFIC SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on THERMO FISHER SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into THERMO FISHER SCIENTIFIC's regulatory disclosures and financial reporting.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 66.02 Phantom Stock Units tied to common shares. These units were credited on March 28, 2026 at a reference price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock and is distributable as stock when his board service ends or upon a change of control. Following this grant, Alexandra holds a total of 1,270.44 Phantom Stock Units directly.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Karen S. Lynch received 66.02 Phantom Stock Units tied to common stock as deferred compensation. These units are credited under the company’s Deferred Compensation Plan for Directors at $473.36 per unit and are convertible into common stock on a 1-for-1 basis.
Following this grant, Lynch holds a total of 291.49 phantom units. The units are scheduled to be distributed in stock after her board service ends for any reason or upon a change of control, aligning compensation with long-term shareholder value.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson received a grant of 66.0200 Phantom Stock Units on March 28, 2026. These units are convertible into Common Stock on a 1-for-1 basis and were credited at $473.36 per unit under the Deferred Compensation Plan for Directors.
Following this grant, Johnson holds a total of 661.3100 Phantom Stock Units. Directors’ retainers are deferred quarterly as Common Stock units based on the closing stock price at quarter end, with shares distributed as stock after director service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 79.2200 Phantom Stock Units on March 28, 2026, as a deferred director retainer. These units are credited under the company’s Deferred Compensation Plan for Directors at a price of $473.36 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this award, Weisler holds a total of 2,717.8900 phantom stock units, which will be distributable as company stock when his board service ends or if there is a change of control.
Thermo Fisher Scientific Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Thermo Fisher common stock, representing 0% of the class as reported. The amendment follows an internal realignment on January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing states the disaggregated entities pursue the same investment strategies previously pursued by The Vanguard Group, Inc.
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earn-out and other performance-based payments. The deal also includes a further $125 million payment due in January 2027 and up to $400 million of earn-out payments tied to Clario’s results in 2026 and 2027.
Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment, enhancing its clinical research data capabilities. Thermo Fisher expects the transaction to generate a double-digit internal rate of return, be accretive to adjusted operating margin, add $0.45 of adjusted EPS in the first year after close, and deliver about $175 million of adjusted operating income synergies by year five.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer sold 1,607 shares of common stock in an open-market transaction. The sale occurred at a price of $499.40 per share, and followed a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025.
After this transaction, Shafer directly holds 20,949.9546 Thermo Fisher Scientific shares. Because the trade was executed under a Rule 10b5-1 plan, its timing reflects a preset schedule rather than a discretionary market-timing decision.
Thermo Fisher Scientific Inc. senior vice president and CFO James Meyer filed an initial ownership statement reporting his equity stake in the company. The filing shows direct ownership of 5,841.4637 shares of common stock and an additional 50.03 shares held indirectly through a 401(k) plan.
He also reports multiple stock option awards on Thermo Fisher common stock with exercise prices ranging from 430.7300 to 635.1000 per share and expiration dates between 2028 and 2035. Individual grants include, for example, 6,851 underlying shares at an exercise price of 513.6800 and 3,598 underlying shares at an exercise price of 430.7300, reflecting substantial unexercised option-based exposure.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 4,000 shares of common stock and reported related trades in Thermo Fisher Scientific Inc. stock. The option exercise, at an exercise price of $0.00 per share, converted into 4,000 shares of common stock.
On the same date, he sold 4,000 shares of common stock in a series of open-market transactions at prices ranging from $503.66 to $519.74, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 125,360.358 shares of common stock.
Additional shares are held indirectly by the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares) and the MNC 2020 Irrevocable Trust (5,000 shares, all as of the reported date), with Casper disclaiming beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.